Safety Assessment of Levulinic Acid and Sodium Levulinate as Used in Cosmetics

Status: Scientific Literature Review for Public Comment
Release Date: February 21, 2020
Panel Meeting Date: June 8-9, 2020

All interested persons are provided 60 days from the above release date (April 21, 2020) to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth.

The Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Lisa A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Preethi S. Raj, M.Sc., Senior Scientific Analyst/Writer.
INTRODUCTION

This scientific literature review is the initial step in preparing a safety assessment of Levulinic Acid and Sodium Levulinate, as used in cosmetic formulations. According to the web-based International Cosmetic Ingredient Dictionary and Handbook (wINCI; Dictionary), Levulinic Acid and Sodium Levulinate both are reported to function in cosmetics as skin conditioning agents; Levulinic Acid is also reported to function as a fragrance ingredient.1

The ingredients reviewed in this safety assessment may be consumed in food, and daily exposure from food use would result in much larger systemic exposures than those from use in cosmetic products. Therefore, the primary objective of the safety assessment of these ingredients as used in cosmetics is on the potential for local effects (e.g., from topical exposure).

Sodium Levulinate is the salt of Levulinic Acid. Upon dissociation in aqueous solution, these ingredients are identical. Thus, these ingredients are reviewed together in this report.

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world’s literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that CIR typically evaluates, is provided on the CIR website (https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites; https://www.cir-safety.org/supplementaldoc/cir-report-format-outline). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Much of the data included in this safety assessment was found on the European Chemicals Agency (ECHA) website.2,3 Please note that the ECHA website provides summaries of information generated by industry, and it is those summary data that are reported in this safety assessment when ECHA is cited. Data from a Research Institute for Fragrance Materials (RIFM) safety assessment pre-proof of Levulinic Acid have also been included, and that assessment is cited when primary references were not available.4

CHEMISTRY

Definition and Structure

Levulinic Acid (CAS No. 123-76-2) is the organic acid that conforms to the structure depicted in Figure 1.1 Levulinic Acid is a 5-carbon, oxocarboxylic, keto acid.5

![Figure 1. Levulinic Acid](image)

Sodium Levulinate (CAS No. 19856-23-6) is the sodium salt of Levulinic Acid1 that conforms to the structure depicted in Figure 2.

![Figure 2. Sodium Levulinate](image)

Physical and Chemical Properties

Levulinic Acid and Sodium Levulinate are both highly soluble in water and comprise carboxylic acid and ketone functional groups.2,3,6,7 While Sodium Levulinate is a solid, sodium salt, Levulinic Acid is a solid with a low melting point, which exhibits limited granularity.2 The physical and chemical properties of Levulinic Acid and Sodium Levulinate are further outlined in Table 1.
Natural Occurrence
Levulinic Acid is found in both natural and processed foods, such as Chinese quince, papaya, rice, sake, and wheaten bread.

Method of Manufacture
While no cosmetic ingredient-specific methods of manufacture were found or submitted, general industrial methods are known. Levulinic Acid can be produced from low grade cellulose, sugar and starchy crops, wood, organic waste, or algae, as a hydrolyzation and conversion step in the biorefinery process. Sugars and starches are the most frequently used feedstock for mass production of Levulinic Acid and typically undergo a multi-step manufacturing process, including hydrolysis of polysaccharides with a Brønsted-Lowry acid (such as sulfuric acid) to yield hexose or pentose sugars (such as glucose), isomerization of glucose by a Lewis acid to yield fructose, dehydration of fructose to 5-(hydroxymethyl)furfural (5-HMF) by a bifunctional acid, and, lastly, rehydration of 5-HMF by a Brønsted-Lowry acid to yield Levulinic Acid. Sodium salts, such as Sodium Levulinate, are typically derived from the reaction of the free acid (e.g., Levulinic Acid) with an inorganic base, such as sodium hydroxide.

Impurities
No impurities data were found in the published literature, and unpublished data were not submitted.

USE
Cosmetic
The safety of the cosmetic ingredients addressed in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredient in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the FDA Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetic industry in response to surveys, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

According to 2020 VCRP survey data, Levulinic Acid is reported to be used in 131 cosmetic formulations, and Sodium Levulinate is reported to be used in 402 cosmetic formulations, of which are leave-on products (Table 2). Results from the 2019 concentration of use survey, conducted by the Council, indicate that Levulinic Acid has the highest maximum concentration of use, at 4.5% in hair dyes, while Sodium Levulinate is used at a maximum concentration of 0.62% in mouthwashes and breath fresheners. The greatest concentrations for leave-on dermal exposure are in foundations containing Levulinic Acid (0.0005%) and eye shadows containing Sodium Levulinate (0.57%).

Additionally, these ingredients have been reported to be used in products that may come into contact with the eyes; for example, both Sodium Levulinate is reported to be used at up to 0.57% in eye shadows and lotions. The use of both ingredients in mouth freshening products, at a reported maximum concentration of 0.35% for Levulinic Acid and 0.62% for Sodium Levulinate, may lead to incidental ingestion and exposure to mucous membranes; frequency of use data were not reported in the VCRP for either ingredient for this use. Sodium Levulinate is reported to be used in face powder formulations (concentration of use not reported), and, could therefore possibly be inhaled. Conservative estimates of inhalation exposures to respirable particles during the use of loose powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.

Both Levulinic Acid and Sodium Levulinate are not restricted from use in any way under the rules governing cosmetic products in the European Union.

Non-Cosmetic
The bulk of Levulinic Acid use is as a chemical intermediate in the manufacture of biofuels and chemicals, fuel extenders, biodegradable polymers, plasticizers, herbicides, and antibiotics. In the US, Levulinic Acid is a food additive approved for human consumption as a flavoring agent and related substance, assuming good manufacturing practices and minimum use to achieve the desired effect. [21 CFR 172 § 515]. Levulinic Acid was included in the list of nonharmful artificial flavoring substances by the Council of Europe in 1974, at 50 ppm. In 1999, the Joint Expert Committee on Food Additives (JECPA) deemed that Levulinic Acid posed no safety concerns. Additionally, Levulinic Acid is proven to be effective in stunting bacterial growth in preserved, ready-to-eat meats and as a cytotoxic agent in oral rinse solutions.

Levulinic Acid appears on the FDA Inactive Ingredient List, and is listed as an inactive ingredient in the manufacturing of buprenorphine transdermal patches. Levulinic Acid has been investigated for its effectiveness in enhancing dermal penetration of drugs.
TOXICOKINETIC STUDIES

Penetration Enhancement

Levulinic Acid

The performance of 3 transdermal buprenorphine patch formulations, combined with 8% (w/w) Levulinic Acid, lauryl alcohol, or Tween 80, was tested upon 1.5 cm x 1.5 cm of abdominal skin from male Sprague-Dawley rats (number not specified). Response surface methodology was used to evaluate the interactive effects of various skin permeation and adhesion properties. The skin flux, and hence penetration potential of buprenorphine, was highest in the presence of Levulinic Acid. The authors postulated that the chemical structure of Levulinic Acid has the potential to disrupt or fluidize lipids in the stratum corneum, hence leading to an increased partitioning and absorption of buprenorphine.

Absorption, Distribution, Metabolism, and Excretion (ADME)

In Vitro

Sodium Levulinate

Livers isolated from male rats (number not specified) were used to observe the metabolism of $[^{13}\text{C}]$levulinate, a levulinate substrate, to 4-hydroxypentanoate in the presence and absence of ethanol. The rat livers were perfused with 4 mM glucose and either (i) nothing – the controls, (ii) 2 mM $[^{13}\text{C}]$levulinate, (iii) 2 mM levulinate + 20 mM ethanol, or (iv) 20 mM ethanol. In contrast to metabolism observed in live rats, ethanol almost doubled the uptake of levulinate in the liver, and tripled the production of 4-hydroxypentanoate from levulinate in the isolated rat livers.

Animal

Intravenous

Sodium Levulinate

A study was conducted in rats to assess if Sodium Levulinate is metabolized into 4-hydroxypentanoate, and whether this process is accelerated in the presence of ethanol. Twelve anesthetized male Sprague-Dawley rats were infused intravenously with a 150 mM solution of Sodium Levulinate at 12 µmol/min/kg/ for 2 h. Half of the rats dosed with Sodium Levulinate received an intraperitoneal bolus of 10% ethanol (1.7 M) in saline at 15 min in an amount calculated to achieve 10 mM ethanol concentration in the body. This bolus was then followed by a continuous intravenous 10% ethanol in saline infusion at 40 µmol/min/kg. The remaining six rats, dosed with Sodium Levulinate, were used as controls and were only infused with saline. Arterial blood was sampled every 20 min for 2 h. Compared to controls, rats infused with ethanol had significantly increased plasma levulinate and 4-hydroxypentanoate concentrations. The authors postulated that this incongruency is due to ethanol decreasing overall levulinate metabolism in vivo, in spite of stimulating the natural reduction of levulinate to 4-hydroxypentanoate.

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

Dermal

Levulinic Acid

The acute dermal toxicity of Levulinic Acid was investigated following a single, semi-occlusive application to Sprague-Dawley rats, in accordance to Organization for Economic Cooperation and Development (OECD) Test Guideline (TG) 402. Five male and 5 female rats were exposed to a single, undiluted dose of 2000 mg/kg and observed for mortality and clinical abnormalities for 15 days. No mortality and signs of toxicity were observed in either sex during the observation period, or at necropsy. Abnormalities at the treated site were absent as well. The acute dermal LD$_{50}$ in rats was therefore determined to be > 2000 mg/kg.

In rabbits, the acute dermal LD$_{50}$ of Levulinic Acid was > 5000 mg/kg. (Details were not provided.)

Oral

Levulinic Acid

The acute oral toxicity of Levulinic Acid was determined in female Sprague Dawley rats, using a single gavage exposure and 14 d observation, followed by necropsy. Initially, 3 rats were dosed at 2000 mg/kg bw in distilled water. All 3 animals died the next day. Hunched posture, piloerection, and decreased activity were observed at the time of dosing. In a second group, 3 female animals were dosed at 300 mg/kg bw in distilled water. No deaths occurred and no signs of toxicity were seen at necropsy. A third group of 3 rats was also dosed at 300 mg/kg bw. No premature deaths occurred, and no signs of toxicity were seen during the necropsy of these animals. No gross or clinical abnormalities were seen in animals that had prematurely died. It was determined that the oral LD$_{50}$ is greater than 300 mg/kg bw, but lower than 2000 mg/kg bw.

In another study, the acute oral LD$_{50}$ of Levulinic Acid in rats was determined to be 1850 mg/kg. (Details were not provided.)
Short-Term Toxicity Studies

Animal
Oral
**Levulinic Acid**

In a short-term toxicity study, 3 groups of 3 rats were fed a diet with 0, 1, or 2% Levulinic Acid for 16 days. No indications of toxicity were observed. (No further details provided.) Guinea pigs were used to investigate the short-term oral toxicity of Levulinic Acid. The animals (number not specified) were given 0.5 to 5.0 mL of 10% Levulinic Acid per day (dosing duration not specified) by means of a 1-mL pippete, or a stomach tube. No gross abnormalities were observed upon necropsy.

Human
Oral
**Levulinic Acid**

Six healthy, human male adults ingested 3 mL of pure Levulinic Acid in 150 to 400 mL of fruit juice on a daily basis, with the exception of Sundays, for 30 days. Clinical and laboratory testing of the resulting biological samples were taken prior to the test substance administration, after 2 wks of administration, and after 4 wks of administration. No significant or cumulative toxic effects were noted in the men, and the immediate hematological effects of the test substance on sugar, non-protein nitrogen, and creatine content were within expected ranges for ingestion of other ordinary foods.

**GENOTOXICITY**

In Vitro

**Levulinic Acid**

In an Ames test, Levulinic Acid was evaluated, in accordance with OECD TG 471, using *Salmonella typhimurium* strains TA98, TA100, TA1537, and *Escherichia coli* strain WP2uvrA. The strains were treated with Levulinic Acid, in water, at concentrations up to 5000 µg/plate. No increase in the mean number of revertant colonies was observed at any tested concentration in the presence or absence of S9 metabolism. (No further details provided.) Levulinic Acid was not considered mutagenic.

Levulinic Acid was assessed in the BlueScreen assay (a screening assay measuring genotoxic stress through human-derived gene expression). Levulinic Acid was found positive for cytotoxicity without metabolic activation, and negative for genotoxicity, both with and without metabolic activation. (No further details provided.)

A chromosomal aberration assay was performed (with and without metabolic activation) in cultured human lymphocytes, in accordance with OECD TG 473, to determine the clastogenic potential of Levulinic Acid. Three treatment series were included in the study. The cells underwent a short, 3-h treatment with the test substance at doses up to 1160 µg/mL in dimethyl sulfoxide (DMSO), both in the absence and presence of metabolic activation. A long-term, continuous treatment followed with the test substance at doses up to 580 µg/mL, only in the absence of metabolic activation, until harvest at 24 h. Appropriate negative and positive controls were included. Following treatment with the test substance, no statistically significant increases in the incidence of cellular aberrations or excluding gaps, were observed.

Levulinic Acid was further examined for mutagenic activity by assaying for the induction of 6-thioguanine resistant mutants in Chinese hamster lung fibroblast V79 cells after in vitro treatment, according to OECD TG 476. A main assay was performed in the absence and presence of S9 metabolism. The test substance was assayed at concentrations of 36.3, 72.5, 145, 290, 580, and 1160 µg/mL. No relevant toxicity was observed at any concentration tested, in the absence or presence of S9 metabolism. It was therefore determined that the test substance does not induce genetic mutation in Chinese hamster VY9 cells, under the the reported experimental conditions.

**DERMAL IRRITATION AND SENSITIZATION**

In Vitro

**Levulinic Acid**

A study to investigate the skin irritation potential of Levulinic Acid was conducted using a reconstructed human epidermis (RHE) model, EPISKIN™, in accordance with OECD TG 439. The test substance, as well as controls, were tested for their ability to impair cell viability after an exposure of 15 minutes followed by a 42 ± 1 hr recovery period. Twenty µL of the test substance, or negative/positive control, was placed in each well. The colorimetric measurement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction (i.e, the assay-driven formation of blue formazan...
salt) was used as an index of cell viability. Results from the blank, negative, and positive controls were as deemed acceptable. The test substance was determined to not be irritating, based upon the measured cell viability above the 60% threshold for skin irritation potential (i.e. 62%).

**Animal**

*Levulinic Acid*

In a dermal irritation study, Levulinic Acid was applied full strength to intact or abraded rabbit skin for 24 h under occlusion. The occlusive exposure of Levulinic Acid was moderately to severely irritating to rabbit skin. (No other details were provided.)

**Human**

*Levulinic Acid*

Levulinic Acid was tested for dermal irritation potential in humans at 4% in petrolatum using a 48-h occlusive patch. No irritation was observed. (No other details were provided.)

**Sensitization**

**In Vitro/In Chemico**

*Sodium Levulinate*

The sensitizing potential of Sodium Levulinate was evaluated using the human cell line activation test (h-CLAT), in accordance to OECD TG 442E. Human monocyctic cells (THP-1) were exposed to eight concentrations of the test substance ranging from 39.1 to 5000 µg/mL in Roswell Park Memorial Institute growth medium (RPMI), for 24 h. The expression of two cell surface antigens, CD86 and CD54 was measured by flow cytometry. Vehicle control (RPMI), negative control (lactic acid), and positive controls (2,4-dinitrochlorobenzene or nickle sulfate) were also run in parallel. The relative fluorescence intensity (RFI) of CD54 was higher than 200% in two experiments of the test substance at 5000 µg/mL. Based on the test positive criteria of CD54 ≥ 200%, the test substance was identified as a potential sensitizer.

**Animal**

*Levulinic Acid*

The ability of Levulinic Acid to induce skin sensitization in female CBA/JN mice, was evaluated using the local lymph node assay (LLNA) according to the OECD TG 442b. The test item was topically administered at concentrations of 5, 10, or 25% (w/w), in a 4:1 ratio of acetone:olive oil, for 3 days. Vehicle controls received acetone and olive oil mixture (13 - 19 animals), while test animals received topical applications at 5% (21 - 27 animals), 10% (29 - 35 animals), or 25% (37 - 43 animals). The positive control group (31 - 45 animals) received 25% (w/w) alpha-hexylcinnamaldehyde, in a 4:1 ratio of acetone and olive oil. After 1 day of no treatment, bromodeoxyuridine /5-bromo-2'-deoxyuridine (BrdU solution) was injected intraperitoneally. One day after the BrdU injection, the animals were killed, auricular lymph nodes were rapidly excised, and cell suspensions were prepared for the evaluation of lymph node proliferation. An increase in the cell proliferation of draining lymph nodes was observed in the low, medium, and high dose groups with a stimulation index (SI) of 1.31, 1.88, and 2.05, respectively, and there was a statistically significant difference between the mid- and high dose groups when compared to the negative control group. The test substance was determined to be a potential skin sensitizer, with SI values higher than 1.6 in the mid and high dose groups.

**Human**

*Levulinic Acid*

A human skin maximization test was conducted on 26 volunteers. The test substance was tested at a concentration of 4% in petrolatum and produced no sensitization reactions. (No further details provided).

**OCULAR IRRITATION STUDIES**

**In Vitro**

*Levulinic Acid*

The potential of Levulinic Acid to cause ocular irritation was investigated in a human cornea model, EpiOcular™ eye irritation test, according to the OECD TG 492. Fifty µL of the test substance was applied to three-dimensional human corneal tissue in duplicate for an exposure time of 30 minutes. After treatment, the test substance was rinsed, and tissue cell viability was evaluated by MTT assay. Demineralized water and methyl acetate were tested concomitantly as negative and positive controls, respectively. The mean tissue viability was found to be 2.5%, which is well below the threshold for irritation potential (≤ 60%). The test substance was considered an eye irritant and capable of inducing serious eye damage.
In accordance with OECD TG 437, Levulinic Acid was further evaluated for the potential for ocular irritancy in a bovine corneal opacity and permeability (BCOP) assay. Using the “closed chamber-method,” 750 µL of the negative control, Hank’s Balanced Salt Solution (HBSS), positive control dimethylformamide, or the test substance were pipetted on to the cornea, which had been incubated with Eagle’s medium without phenol red at 32 ± 1°C for 1 h. The test substance was incubated on the cornea for 10 min at 32 ± 1°C. Post-removal of the test substance and 2 h post-incubation, corneal opacity and permeability values were measured. The calculated in vitro irritancy score (IVIS) was 84.29 which is within the range for classification for a substance causing serious eye damage.

**SUMMARY**

This report addresses the safety of Levulinic Acid and Sodium Levulinate, a carboxylic acid and its salt. According to the Dictionary, Levulinic Acid and Sodium Levulinate are reported to function as skin conditioning agents in cosmetics, while Levulinic Acid is also a fragrance ingredient. According to 2019 concentration of use data obtained by the Council, the highest concentration of use of Levulinic Acid is in hair dyes, at 4.5%, and the highest concentration of use of Sodium Levulinate is in mouthwashes and breath fresheners at 0.62%. Both Levulinic Acid and Sodium Levulinate are used in products which involve dermal and mucous membrane contact, and Sodium Levulinate could possibly be inhaled, as it is used in face powder formulations. Non-cosmetic uses include manufacturing of biofuels, chemicals, fuel extenders, plasticizers, pharmaceuticals, food additives and flavoring, and as inactive ingredients in approved drugs.

Three transdermal buprenorphine TDD patch formulations were tested for penetration using 8% (w/w) Levulinic Acid, lauryl alcohol, or Tween 80. The penetration potential of buprenorphine was highest in the presence of Levulinic Acid.

Isolated male rat livers were used to observe the metabolism of Levulinic Acid to 4-hydroxypentanoate in the absence and presence of ethanol. Ethanol almost doubled the uptake of levulinate, and tripled the production of 4-hydroxypentanoate from levulinate in the isolated rat livers.

Anesthetized male Sprague-Dawley rats were infused intravenously with a 150 mM solution of Sodium Levulinate at 12 µmol/min/kg for 2 h. Half of these rats then received an intraperitoneal bolus of 10% ethanol 15 minutes after the exposure to Sodium Levulinate, while the other half only received saline (control). Compared to controls, the rats infused with ethanol had significantly increased plasma levulinate and 4-hydroxypentanoate concentrations.

The acute dermal LD₅₀ of a semi-occlusive application of Levulinic Acid in Sprague-Dawley rats was determined to be > 2000 mg/kg. The acute dermal LD₅₀ in rabbits exceeded 5000 mg/kg.

Female Sprague-Dawley rats were dosed by gavage with Levulinic Acid. Animals dosed with 2000 mg/kg bw died the following day. After 2 groups of 3 rats were dosed with 500 mg/kg bw without dying prematurely or showing signs of toxicity, the acute toxicity estimate was determined to be greater than 300 mg/kg bw, but lower than 2000 mg/kg bw. In another study, the acute oral LD₅₀ of Levulinic Acid in rats was determined to be 1850 mg/kg.

In short-term oral toxicity studies with Levulinic Acid, no signs of toxicity or gross abnormalities were observed in rats or guinea pigs. Similarly, in humans, no significant immediate or cumulative toxic effects were observed when 6 male subjects ingested 3 mL of Levulinic Acid daily in fruit juice over the course of 4 weeks.

In an Ames test, Levulinic Acid was evaluated at concentrations up to 5000 µg/plate in S. typhimurium strains TA98, TA100, TA1537, and E. coli WP2uvrA strains. No increase in revertant colonies was observed in the presence or absence of metabolic activation. Levulinic Acid was determined to be non-mutagenic. In a BlueScreen assay, Levulinic Acid was found positive for cytotoxicity without metabolic activation, and negative for genotoxicity, both with and without metabolic activation. Levulinic Acid was assayed at various concentrations to test its ability to induce chromosomal damage in cultured human lymphocytes, and 6-thioguanine resistant mutants in Chinese hamster V79 cells, in the presence and absence of metabolic activation. No toxicity was observed in either study at any concentration tested, in the presence or absence of metabolic activation.

Levulinic Acid was determined to not be irritating in the EPISKIN™ assay. In a dermal irritation study in which Levulinic Acid was applied full strength to intact or abraded rabbit skin for 24 h under occlusion, moderate to severe irritation was observed. When Levulinic Acid was tested at 4% in petrolatum in a 48 h occluded patch test in humans, no irritation was observed.

The sensitizing potential of Sodium Levulinate was evaluated using the human cell line activation test (h-CLAT), and the test substance was identified as a potential sensitizer. In a LLNA, Levulinic Acid (evaluated at 5, 10, and 25% (w/w)) was determined to be a potential skin sensitizer. In a human skin maximization test, 26 volunteers were exposed to 4% Levulinic Acid in petrolatum. No sensitization reactions occurred.

Levulinic Acid was determined to potentially cause ocular irritation and serious eye damage in the EpiOcular™ assay. Levulinic Acid was further evaluated in a BCOP assay, and the calculated in vitro irritancy score was within the range of causing serious eye damage.
INFORMATION SOUGHT

The CIR is seeking the following information on Levulinic Acid and Sodium Levulinate for use in the resulting safety assessment:

- Method of manufacture for cosmetics
- Impurities
- Dermal irritation and sensitization data at maximum concentration of use
### Table 1. Physical and Chemical Properties of Levulinic Acid and Sodium Levulinate

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Levulinic Acid</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Form (@ 20°C &amp; 1013 hPa)</td>
<td>solid</td>
<td></td>
</tr>
<tr>
<td>Color</td>
<td>white-pale yellow</td>
<td></td>
</tr>
<tr>
<td>Molecular Weight (g/mol)</td>
<td>116.11</td>
<td></td>
</tr>
<tr>
<td>Density/Specific Gravity (@ 20°C)</td>
<td>1.1398</td>
<td></td>
</tr>
<tr>
<td>Topological Polar Surface Area (Å²)</td>
<td>54.4</td>
<td></td>
</tr>
<tr>
<td>Vapor pressure (mmHg @ 20°C, 25°C)</td>
<td>0.00281; 0.00464</td>
<td></td>
</tr>
<tr>
<td>Melting Point (°C)</td>
<td>27.21 - 29.56</td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C)</td>
<td>251.70 - 252.20</td>
<td></td>
</tr>
<tr>
<td>Water Solubility (g/L @ 20°C &amp; pH = 1)</td>
<td>791.3</td>
<td></td>
</tr>
<tr>
<td>Ethanol Solubility</td>
<td>very soluble</td>
<td></td>
</tr>
<tr>
<td>log Kow (@ pH = 2, 20°C)</td>
<td>0.498</td>
<td></td>
</tr>
<tr>
<td>Disassociation constants (pKa, @ 20°C)</td>
<td>4.62</td>
<td></td>
</tr>
<tr>
<td><strong>Sodium Levulinate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Form (@ 20°C &amp; 1013 hPa)</td>
<td>solid, powder</td>
<td></td>
</tr>
<tr>
<td>Color</td>
<td>white-off-white</td>
<td></td>
</tr>
<tr>
<td>Molecular Weight (g/mol)</td>
<td>138.1</td>
<td></td>
</tr>
<tr>
<td>Density/Specific Gravity (@ 20°C)</td>
<td>1.4795/ml</td>
<td></td>
</tr>
<tr>
<td>Topological Polar Surface Area (Å²)</td>
<td>57.2</td>
<td></td>
</tr>
<tr>
<td>Particle size Distribution (D50; μm)</td>
<td>154.7</td>
<td></td>
</tr>
<tr>
<td>Vapor pressure (mmHg @ 135°C)</td>
<td>0.000139</td>
<td></td>
</tr>
<tr>
<td>Melting Point (°C)</td>
<td>170.2</td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C)</td>
<td>not observed; decomposition &gt; 274.6</td>
<td></td>
</tr>
<tr>
<td>Water Solubility (g/L @ 20°C &amp; pH = 8)</td>
<td>797.2</td>
<td></td>
</tr>
<tr>
<td>log Kow (@ pH = 2, 20°C)</td>
<td>-0.616</td>
<td></td>
</tr>
<tr>
<td>Disassociation constants (pKa)</td>
<td>9.38</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. 2020 Frequency of use\(^{11}\) and 2019 concentration of use\(^{12}\) data, according to duration and type of exposure

<table>
<thead>
<tr>
<th>Duration of Use</th>
<th># of Uses(^{11})</th>
<th>Max Conc of Use (%)(^{12})</th>
<th># of Uses(^{11})</th>
<th>Max Conc of Use (%)(^{12})</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Levulinic Acid</td>
<td>Sodium Levulinate</td>
<td>Levulinic Acid</td>
<td>Sodium Levulinate</td>
</tr>
<tr>
<td><strong>Totals</strong>*</td>
<td>131</td>
<td>0.0005-4.5</td>
<td>402</td>
<td>0.0005-0.62</td>
</tr>
<tr>
<td><strong>Exposure Type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye Area</td>
<td>35</td>
<td>NR</td>
<td>50</td>
<td>0.57</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>0.2-0.35</td>
<td>NR</td>
<td>0.18-0.62</td>
</tr>
<tr>
<td>Incidental Inhalation-Spray</td>
<td>19°, 40°</td>
<td>0.2-0.35(^{a})</td>
<td>NR</td>
<td>0.18-0.62</td>
</tr>
<tr>
<td>Incidental Inhalation-Powder</td>
<td>40°</td>
<td>NR</td>
<td>5; 97°; 2(^{a})</td>
<td>0.002-0.0072(^{b})</td>
</tr>
<tr>
<td>Dermal Contact</td>
<td>129</td>
<td>0.0005</td>
<td>394</td>
<td>0.0005-0.57</td>
</tr>
<tr>
<td>Deodorant (underarm)</td>
<td>NR</td>
<td>NR</td>
<td>1(^{a})</td>
<td>NR</td>
</tr>
<tr>
<td>Hair - Non-Coloring</td>
<td>2</td>
<td>0.48</td>
<td>8</td>
<td>NR</td>
</tr>
<tr>
<td>Hair-Coloring</td>
<td>NR</td>
<td>4.5</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Nail</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Mucous Membrane</td>
<td>2</td>
<td>0.2-0.35</td>
<td>65</td>
<td>0.18-0.62</td>
</tr>
<tr>
<td>Baby Products</td>
<td>1</td>
<td>NR</td>
<td>3</td>
<td>0.35</td>
</tr>
</tbody>
</table>

*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

\(^{a}\)It is possible these products are sprays, but it is not specified whether the reported uses are sprays.

\(^{b}\)Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories

\(^{c}\)It is possible these products are powders, but it is not specified whether the reported uses are powders

NR – no reported use
REFERENCES


